Skip to main content
SpringerLink
Log in

Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 2020. https://doi.org/10.3390/cancers12030738.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Eggermont AMM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643–54. https://doi.org/10.1016/S1470-2045(21)00065-6.

    Article  CAS  PubMed  Google Scholar 

  3. Grossman K, Othus M, Pratel S, et al. Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pemnbrolizumab in patients with high-risk resected melanoma. J Clin Oncol. 2021;39:9501.

    Article  Google Scholar 

  4. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35. https://doi.org/10.1056/NEJMoa1709030.

    Article  CAS  PubMed  Google Scholar 

  5. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90. https://doi.org/10.1245/s10434-007-9747-3.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Dr. Karakousis is supported by the National Cancer Institute SPORE in skin cancer award number P50 CA 261608.

Author information

Authors and Affiliations

  1. Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Cimarron E. Sharon MD & Gabriella N. Tortorello MD

  2. Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Kevin Ma BS, Giorgos C. Karakousis MD & John T. Miura MD

  3. Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA

    Andrew J. Sinnamon MD, MSCE

  4. Division of Medical Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Tara C. Mitchell MD

Authors
  1. Cimarron E. Sharon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriella N. Tortorello MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin Ma BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew J. Sinnamon MD, MSCE
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tara C. Mitchell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giorgos C. Karakousis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John T. Miura MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cimarron E. Sharon MD.

Ethics declarations

Disclosures

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 20 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharon, C.E., Tortorello, G.N., Ma, K. et al. Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma. Ann Surg Oncol 30, 5329–5332 (2023). https://doi.org/10.1245/s10434-023-13736-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-13736-5

Search

Navigation